Open AccessAn Audit of a Protocol Showing the Effects of Withdrawal of Selegiline from Patients with Parkinson's Disease
Author(s) -
Douglas G MacMahon,
Ross Bland,
R. P. Maguire,
Stephen Campbell
Publication year - 1997
Publication title -
age and ageing
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.014
H-Index - 143
eISSN - 1468-2834
pISSN - 0002-0729
DOI - 10.1093/ageing/26.suppl_3.p13-a
Subject(s) - selegiline , medicine , agonist , parkinson's disease , anesthesia , pharmacology , disease , receptor
Results 123 (61%) were on S, 103 had complete data available 84 patients (81%) resumed or continued selegiline. Of these. 43 (42%) remained on, or resumed 10 mg. dose. 39(37%) resumed 5mg, and 1 (1%) each 2.5 or 1.25 mg. Only 19 (18%) patients stopped S and remained off it Of these, no change in PD medications 7; Increased dopa 6 (ave. +200mg (+32%), Decreased dopa 1 ; Increased agonist 2 (400% increase), Added agonist 1 ; Changed agonist 1
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom